Lesinurad联合别嘌醇治疗痛风:CLEAR 2随机双盲安慰剂对照研究
CLEAR 2是一项为期12个月的III期随机双盲试验,纳入610例别嘌醇治疗后血尿酸仍不达标的痛风患者。加用lesinurad 200 mg或400 mg较单用别嘌醇显著提高第6个月sUA达标率(55.4%、66.5% vs 23.3%,P<0.0001);关键次要终点无统计学显著获益,200 mg剂量安全性总体可接受。
要点
- lesinurad 200 mg与400 mg联合别嘌醇均显著提高第6个月sUA达标率,优于单用别嘌醇。
- 痛风 flare 发生率与痛风石完全消解等关键次要终点未见支持lesinurad的统计学显著差异。
- 200 mg剂量安全性与其他别嘌醇单药治疗相当,肾相关不良事件随剂量升高。
核心结论
- 在别嘌醇治疗后sUA仍高于目标的痛风患者中,加用lesinurad可显著提高sUA达标率,且200 mg剂量总体耐受性良好。
研究设计与样本
- 12个月随机、双盲、安慰剂对照III期多国研究(CLEAR 2),共纳入610例患者。
- 入组患者需别嘌醇≥300 mg(中度肾功能不全者≥200 mg)、筛查时sUA≥6.5 mg/dL(≥387 µmol/L)且既往一年内有≥2次痛风发作。
- 主要终点为第6个月sUA<6.0 mg/dL(<357 µmol/L)的患者比例。
主要发现
- 患者以男性为主,平均(±SD)年龄51.2±10.90岁,痛风病程11.5±9.26年,基线sUA 6.9±1.2 mg/dL(410±71 µmol/L)。
- 第6个月sUA达标率:lesinurad 200 mg+别嘌醇55.4%、400 mg+别嘌醇66.5%、单用别嘌醇23.3%(两组lesinurad+别嘌醇对比单药均p<0.0001)。
- 关键次要终点(第7至12个月需治疗的痛风发作率、第12个月≥1个目标痛风石完全消解比例)未见支持lesinurad的统计学显著差异。
- 肾相关不良事件发生率:200 mg组5.9%、400 mg组15.0%、单用别嘌醇组4.9%;血清肌酐≥1.5倍基线者分别为5.9%、15.0%、3.4%。
- 严重治疗中出现的不良事件发生率:200 mg组4.4%、400 mg组9.5%、单用别嘌醇组3.9%。
关键数值与推荐
- 主要终点达标定义:第6个月sUA<6.0 mg/dL(<357 µmol/L)。
- 入组sUA阈值:筛查时≥6.5 mg/dL(≥387 µmol/L)。
- 别嘌醇基础剂量:≥300 mg,中度肾功能不全者≥200 mg。
临床怎么用
- 对别嘌醇单药sUA不达标且既往发作频繁的痛风患者,可考虑加用lesinurad 200 mg以促进sUA达标。
- 用药期间需监测肾功能与血清肌酐,关注肾相关不良事件,400 mg剂量肾相关事件明显增多。
局限性
- 关键次要终点未见统计学显著获益,降尿酸达标能否转化为痛风发作与痛风石获益尚不明确。
- 原文未报告安慰剂对照(研究为加用lesinurad与单用别嘌醇比较)及长期结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with serum uric acid (sUA) above target in a 12-month, randomised, phase III trial. METHODS: Patients on allopurinol ≥300 mg (≥200 mg in moderate renal impairment) had sUA level of ≥6.5 mg/dL (≥387 µmol/L) at screening and two or more gout flares in the prior year. Primary end point was the proportion of patients achieving sUA level of <6.0 mg/dL (<357 µmol/L) (month 6). Key secondary end points were mean gout flare rate requiring treatment (months 7 through 12) and proportions of patients with complete resolution of one or more target tophi (month 12). Safety assessments included adverse events and laboratory data. RESULTS: Patients (n=610) were predominantly male, with mean (±SD) age 51.2±10.90 years, gout duration 11.5±9.26 years and baseline sUA of 6.9±1.2 mg/dL (410±71 µmol/L). Lesinurad at 200 and 400 mg doses, added to allopurinol, significantly increased proportions of patients achieving sUA target versus allopurinol-alone therapy by month 6 (55.4%, 66.5% and 23.3%, respectively, p<0.0001 both lesinurad+allopurinol groups). In key secondary end points, there were no statistically significant treatment-group differences favouring lesinurad. Lesinurad was generally well tolerated; the 200 mg dose had a safety profile comparable with allopurinol-alone therapy. Renal-related adverse events occurred in 5.9% of lesinurad 200 mg+allopurinol, 15.0% of lesinurad 400 mg+allopurinol and 4.9% of allopurinol-alone groups, with serum creatinine elevation of ≥1.5× baseline in 5.9%, 15.0% and 3.4%, respectively. Serious treatment-emergent adverse events occurred in 4.4% of lesinurad 200 mg+allopurinol, in 9.5% of lesinurad 400 mg+allopurinol and in 3.9% of allopurinol-alone groups, respectively. CONCLUSION: Lesinurad added to allopurinol demonstrated superior sUA lowering versus allopurinol-alone therapy and lesinurad 200 mg was generally well tolerated in patients with gout warranting additional therapy. TRIAL REGISTRATION NUMBER: NCT01493531.
引用
- Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2016. PMID: 27821644. doi:10.1136/annrheumdis-2016-209213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。